Bluebird bio Inc

NASDAQ:BLUE   3:59:50 PM EDT
28.78
+0.66 (+2.35%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.93B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$11.32 Million
Adjusted EPS-$3.02
See more estimates
10-Day MA$28.64
50-Day MA$30.37
200-Day MA$47.48
See more pivots

Bluebird bio Inc Stock, NASDAQ:BLUE

60 Binney Street, 60 Binney Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.339.499.9300
Number of Employees: 1213

Description

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.